HighTower Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

HighTower Advisors’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-17,331	Closed	-$162K	–	2091
2016 Q1	$162K	Buy	17,331 +4,730	+38%	+$50.9K	﹤0.01%	1845
2015 Q4	$193K	Buy	+12,601	New	+$211K	﹤0.01%	1758

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HighTower Advisors's MNTA Position: Q2 2016 in Review

HighTower Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2016, closing a stake of 17,331 shares — an estimated $162K sold.

HighTower Advisors first reported a position in MNTA in Q4 2015 and held it in 2 quarters. The position peaked at $193K in Q4 2015. 146 funds tracked by Wall St. Rank hold MNTA as of Q2 2016.

HighTower Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
HighTower Advisors sold 17,331 Momenta Pharmaceuticals, Inc. shares in Q2 2016, an estimated $162K.
HighTower Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
HighTower Advisors's Momenta Pharmaceuticals, Inc. position peaked at $193K in Q4 2015.
146 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2016.

Based on HighTower Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.